QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BHVN

QT80Biohaven Ltd.
NYSE·Healthcare·Biotechnology·USA
Latest market price
13.57
-0.05-0.37%
OverviewShort InterestFilings
BHVNQT80Biohaven Ltd.·NYSE
OverviewShort InterestFilings
13.57-0.37%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-15.26
Insider Own8.32%
Shs Outstand150.56M
Perf Week19.35%
Market Cap1.44BForward P/E-EPS next Y-2.44Insider Trans0.04%Shs Float-Perf Month61.74%
Enterprise Value1.45BPEG-EPS next Q-0.78Inst Own-Short Float-Perf Quarter51.45%
Income-464431432.00P/S0.00EPS this Y80.37%Inst Trans-Short Ratio-Perf Half Y23.03%
Sales-P/B15.53EPS next Y18.46%ROA-138.87%Short Interest-Perf YTD20.19%
Book/sh0.86P/C-EPS next 5Y-ROE-866.46%52W High18.57 -26.93%Perf Year-6.80%
Cash/sh2.31P/FCF-EPS past 3/5Y-ROIC-155.69%52W Low7.48 81.42%Perf 3Y-
Dividend Est.-EV/EBITDA-2.28Sales past 3/5Y-Gross Margin0.00%Volatility6.21% 6.01%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM38.90%Oper. Margin0.00%ATR (14)0.95Perf 10Y-
Dividend Ex-Date-Quick Ratio7.41Sales Y/Y TTM-Profit Margin0.00%RSI (14)70.50Recom2.50
Dividend Gr. 3/5Y-Current Ratio7.41EPS Q/Q59.45%SMA2021.45%Beta1.32Target Price17.60
Payout0.00%Debt/Eq2.21Sales Q/Q-SMA5032.01%Rel Volume2.54Prev Close13.62
Employees256LT Debt/Eq5.37EarningsAug 10SMA20017.31%Avg Volume2.54MPrice13.57
IPO DateSep 23, 2022Option/ShortYes / YesEPS/Sales Surpr.-2.33% -Net Debt/EBITDA-0.02Volume6,458,273Change-0.37%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedMorgan StanleyOverweight$26 → $18
Mar-04-26ReiteratedH.C. Wainwright$11 → $10
Mar-03-26ReiteratedLeerink PartnersOutperform$60 → $15
Feb-05-26InitiatedGoldman SachsBuy$23
Jan-21-26UpgradeRBC CapitalSector Perform → Outperform$61 → $22
Dec-03-25ReiteratedH.C. Wainwright$59 → $11
Dec-03-25DowngradeHC Wainwright & Co.Buy → Neutral
Nov-26-25DowngradeUBSBuy → Neutral$11
Nov-18-25ReiteratedMorgan StanleyOverweight$58 → $26
Nov-06-25DowngradeBernsteinOutperform → Market Perform
Latest News
Jun-18-26
Jun-18-2603:28PM
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study InitiationsSeekingAlpha
12:02AM
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline UpdatesYahoo
Jun-12-26
Jun-12-2609:31AM
Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
19000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A4440
Gross Profit145-40
Selling, General and Administrative Excl. Other57210689
Research and Development253635796
Other Operating Expense6200
Operating Income-742-745-885
Interest Expense-700
Unusual Expense
———
Non-Operating Income (Expense)-216-8-39
Net Income Before Taxes-503-737-846
Income Taxes1711
Consolidated Net Income-889-739-846
Net Income From Continuing Operations-521-739-846
Net Income-889-739-846
EPS (Recurring)-15.26-6.86-9.28
EPS (Basic, Before Extraordinaries)-15.26-6.86-9.28
EPS (Diluted)-15.26-6.86-9.28
EBITDA-481-727-838
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
4.64——
Gross Margin
76.32——
Operating Margin
-390.53——
Net Margin
-467.89——
Shares Outstanding6510891
Market Capitalization8821,219—
Operating Lease Expense
———
Insider Trading Volume
$14.90$13.47$12.04$10.62$9.19● Close Price0.00M8.29M16.57M24.86M33.14MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
CHILDS JOHN WDirectorMar 04 '25Buy30.4561,1001,860,3542,323,971Mar 09 12:00 AM
Buten MatthewChief Financial OfficerJan 05 '26Option Exercise0.008,5000198,246Jan 07 12:00 AM
Gentile KimberlySVP, Clinical OperationsJan 05 '26Option Exercise0.007,5000101,513Jan 07 12:00 AM
Coric VladChief Executive OfficerJan 05 '26Option Exercise0.0028,50001,811,398Jan 07 12:00 AM
Car BruceChief Scientific OfficerJan 05 '26Option Exercise0.009,500010,096Jan 07 12:00 AM
Clark George C.VP, Chief Accounting OfficerJan 05 '26Option Exercise0.005,000068,095Jan 07 12:00 AM
Clark George C.VP, Chief Accounting OfficerNov 17 '25Buy8.5217,000144,77020,000Nov 18 12:00 AM
Bailey GregoryDirectorNov 13 '25Buy7.50400,0003,000,0002,020,071Nov 17 12:00 AM
CHILDS JOHN WDirectorNov 13 '25Buy7.503,333,33324,999,9985,653,904Nov 17 12:00 AM
Coric VladChief Executive OfficerNov 13 '25Buy7.50666,6664,999,9961,195,275Nov 17 12:00 AM
CHILDS JOHN WDirectorApr 22 '24Buy41.00268,29110,999,9314,096,512Mar 05 12:00 AM
Car BruceChief Scientific OfficerJan 05 '25Option Exercise0.009,500014,250Jan 07 12:00 AM
Gentile KimberlySVP, Clinical OperationsJan 05 '25Option Exercise0.007,500099,719Jan 07 12:00 AM
Clark George C.VP, Chief Accounting OfficerJan 05 '25Option Exercise0.005,000066,168Jan 07 12:00 AM
Buten MatthewChief Financial OfficerJan 05 '25Option Exercise0.008,5000196,013Jan 07 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR